Merck's Bid To Block Expert Testimony Mostly Fails

Law360, New York (July 28, 2009, 2:11 PM EDT) -- The judge in charge of the multidistrict litigation over the osteoporosis drug Fosamax has rejected Merck & Co.'s bid to exclude three experts' general causation testimony, but granted the drugmaker's bid to bar the expert testimony of an epidemiologist.

In a 105-page opinion, Judge John F. Keenan of the U.S. District Court for the Southern District of New York gave a mixed ruling Monday on omnibus Daubert motions filed by Merck and by the plaintiffs.

The plaintiffs in the MDL claim they developed a bone degenerative...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.